Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032968 · ClinicalTrials.gov registry record · Phase 3
Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1
A Phase 3 study of Heroin Dependence and Substance Withdrawal Syndrome, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 3
- Development phase
- 341
- Enrollment target
- 7
- Study locations
NCT00032968: Completed Phase 3 study of Heroin Dependence and Substance Withdrawal Syndrome, sponsored by University of California, Los Angeles.
NCT00032968 is a Phase 3 study of Heroin Dependence and Substance Withdrawal Syndrome that has completed, run by University of California, Los Angeles. The registered enrollment target is 341 participants, above the 67-participant average among 8 other Heroin Dependence trials with a reported enrollment target (409% higher). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00032968, a Phase 3 study of Heroin Dependence and Substance Withdrawal Syndrome, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 341 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to assess buprenorphine/naloxone versus clonidine for outpatient opiate detoxification.
Conditions Studied
Interventions
- DRUG Buprenorphine/naloxone
Study Locations (7)
California
- Haight-Ashbury Free Clinic - Berkeley
- Aegis Medical Systems, Inc. - Oxnard
New York
- Addiction Research and Treatment Corp - Brooklyn
- Bellevue - New York
Indiana
- Midtown Community Mental Health Center - Indianapolis
New Jersey
- UMDNJ - Robert Wood Johnson Medical School - Piscataway
Oregon
- Kaiser Permanente Northwest, Division of Addiction - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2001-01 |
| Est. Completion | 2002-08 |
| Phase | Phase 3 |
What the finished NCT00032968 record still lists
NCT00032968 is an interventional study that assigns participants to a tested intervention. The registered 341 participants enrollment target is mid-sized for trials with a published cap, above the 67-participant average among 8 other Heroin Dependence trials with a reported enrollment target (409% higher).
The record links to 3 conditions, with Heroin Dependence appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine/naloxone is the first listed.
NCT00032968 lists 7 locations in 5 states (California, New York, Indiana).
Frequently Asked Questions
What is clinical trial NCT00032968 about?
NCT00032968 is a clinical study titled "Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1". The purpose of this study is to assess buprenorphine/naloxone versus clonidine for outpatient opiate detoxification.
What is the current status of trial NCT00032968?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 341 participants. The study started on 2001-01. Estimated completion is 2002-08.
What conditions does trial NCT00032968 study?
This clinical trial studies the following conditions: Heroin Dependence, Substance Withdrawal Syndrome, Morphine Dependence.
What interventions are being tested in trial NCT00032968?
The interventions under investigation include: Buprenorphine/naloxone (DRUG).
Who is sponsoring clinical trial NCT00032968?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00032968 being conducted?
This trial has 7 study locations across California, Indiana, New Jersey, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heroin Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00032968's enrollment target sits among peer trials
341 1st of 8 higher than 8 of 8 other Heroin Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heroin Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
COMPLETED · Phase 3
-
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
COMPLETED · Phase 3
-
Study Comparing Liquid and Tablet Buprenorphine Formulations - 5
COMPLETED · Phase 3
-
Directly Administered HIV Therapy in Methadone Clinics
COMPLETED · Phase 2
-
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
COMPLETED · Phase 2
-
Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06852170 · 341 participants · NA
Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
- NCT05714085 · 342 participants · Phase 2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- NCT06188702 · 342 participants · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia